Ixabepilone + Carboplatin Metastatic Breast Cancer

Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+
and triple negative breast cancer. Ixabepilone has substantial antitumor activity in
taxane-refractory patients and novel combinations are needed in this poor prognosis
population. Carboplatin in combination with gemcitabine or paclitaxel has activity in
metastatic breast cancer (MBC); there is also demonstrated activity of the
gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A Phase I
study of ixabepilone plus carboplatin in solid tumor patients demonstrated the safety of
this combination at the doses and schedule proposed for this Phase II trial (BMS data on
file).